Home > > Healthcare > > Mastitis Market Size, Share, Growth, Trends, Uses & Industry Forecast (2032)
ID : CBI_1730 | Updated on : | Author : Amit Sati | Category : Healthcare
Mastitis Market is estimated to reach over USD 3.16 Billion by 2032 from a value of USD 1.85 Billion in 2024 and is projected to grow by USD 1.96 Billion in 2025, growing at a CAGR of 6.2% from 2025 to 2032.
Mastitis is an inflammatory condition of the mammary gland and udder tissue, typically caused by bacterial infections that enter through the teat canal. It is the most significant disease in the dairy industry, leading to physical and chemical changes in milk composition and substantial economic losses due to reduced yield and treatment costs. Further, key trends driving the market include rapid adoption of precision livestock farming technologies, such as automated milking systems and AI-powered health sensors, which enable real-time detection and personalized herd management. Moreover, the sector is witnessing a significant shift toward antimicrobial stewardship, fostering a growing demand for non-antibiotic alternatives, including vaccines, teat sealants, and immunostimulants to combat rising resistance and meet consumer preferences for residue-free dairy.
AI is revolutionizing the market by transitioning dairy management from reactive treatment to predictive, precision-based care. By leveraging machine learning and deep learning algorithms, AI-powered systems analyze real-time data from IoT sensors, automated milking robots, and infrared thermography to detect subtle physiological changes such as udder temperature spikes or altered milk conductivity. These advanced models, including artificial neural networks, integrate multi-omics and somatic cell count data to provide highly accurate, cow-side diagnoses. This proactive approach significantly reduces reliance on broad-spectrum antibiotics, minimizes milk waste, and enhances animal welfare by enabling early, targeted interventions that preserve herd productivity and farm profitability.
Rising global demand for dairy products, particularly in emerging economies, is intensifying pressure on producers to maximize yield while maintaining stringent milk quality standards, directly fueling the mastitis market. Further, to stay competitive, dairy operations are rapidly integrating precision livestock technologies, such as AI-driven sensors and automated milking systems, which facilitate the continuous monitoring of individual cow health. These technological advancements enable the early detection of sub-clinical infection before visual symptoms appear, allowing for targeted interventions that minimize milk waste and antibiotic use.
Thus, the growing need for milk and milk-based products, along with the integration of AI and automation technologies, contributes significantly to the mastitis market size.
The market faces significant barriers due to stringent regulatory frameworks and poor treatment adherence in developing regions. In highly regulated markets like the EU and North America, strict mandates on antibiotic residues and maximum residue limits force frequent milk disposal, imposing heavy financial burdens on producers and deterring intensive treatment. Simultaneously, in emerging economies, limited awareness and rural isolation lead to low adherence to standardized veterinary protocols, such as improper withdrawal periods or uncompleted drug courses. These factors collectively foster antimicrobial resistance and increase disease recurrence, ultimately stifling overall market revenue and slowing the adoption of advanced therapeutic solutions.
The increasing focus on non-antibiotic alternatives is creating significant market opportunities as the dairy industry faces mounting pressure from antimicrobial resistance and stringent residue regulations. This shift is accelerating the research and commercialization of diverse solutions, including vaccines to enhance herd immunity, bacteriophage therapies that specifically target infection pathogens, and herbal-based anti-inflammatories. These alternatives are particularly attractive to producers because they eliminate milk withdrawal periods, thereby preventing the economic loss associated with discarded milk. Furthermore, the rising consumer preference for organic and residue-free dairy products is driving a premium market for manufacturers that prioritize sustainable, antibiotic-free therapeutic portfolios.
Thus, availability of alternatives such as vaccines & bacteriophage therapies and preference for organic and residue-free dairy drive the mastitis market opportunities.
Based on the disease type, the market is segmented into clinical mastitis and sub-clinical mastitis.
Trends in the Disease Type:
Clinical mastitis accounted for the largest revenue portion in the year 2024 and is anticipated to register a significant CAGR during the forecast period.
Based on the treatment, the market is segmented into antibiotics, vaccines, painkillers/NSAIDs, and teat sealants & disinfectants.
Trends in the Treatment:
Antibiotics accounted for the largest revenue share of 71.25% in the year 2024.
Vaccines is anticipated to register the fastest CAGR during the forecast period.

Based on the diagnostics, the market is segmented into on-farm culture kits, PCR tests, automated milk analyzers, handheld detectors, and others.
Trends in the Diagnostics:
On-Farm Culture Kits accounted for the largest revenue share in the year 2024 and is anticipated to register the fastest CAGR during the forecast period.
Based on the end user, the market is segmented into dairy farms & cooperatives, veterinary hospitals & clinics, and research & diagnostic laboratories.
Trends in the End User:
Veterinary Hospitals & Clinics accounted for the largest revenue share in the year 2024.
Dairy Farms & Cooperatives is anticipated to register the fastest CAGR during the forecast period.
The regions covered are North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Asia Pacific region was valued at USD 0.46 Billion in 2024. Moreover, it is projected to grow by USD 0.49 Billion in 2025 and reach over USD 0.81 Billion by 2032. Out of this, China accounted for the maximum revenue share of 32.15%. The market growth is mainly driven by the massive and expanding cattle population and the rising demand for high-quality dairy products, which necessitates more rigorous herd health management. The market development is further accelerated by the rapid modernization of dairy farms, increasing government initiatives for milk safety, and a surge in awareness regarding the economic impact of sub-clinical mastitis.

North America is estimated to reach over USD 1.15 Billion by 2032 from a value of USD 0.67 Billion in 2024 and is projected to grow by USD 0.71 Billion in 2025. The North American market is primarily driven by highly industrialized dairy infrastructure, stringent government regulations on milk quality, and the rapid adoption of advanced precision technologies like automated milking sensors and rapid diagnostic kits.
The regional trends analysis depicts that stringent regulation and accelerating shift toward selective dry cow therapy, non-antibiotic treatments, and advanced diagnostic technologies in Europe are driving the market. Additionally, the factors driving the market in the Middle East and African region are the steady rise of the commercial dairy sector and increasing government and private investments in improving veterinary infrastructure and herd hygiene. Further, increasing transition toward large-scale, commercialized dairy farming and a rising emphasis on improving milk quality in the Latin America region are driving the market.
The global mastitis market is highly competitive with major players providing solutions to the national and international markets. Key players are adopting several strategies in research and development (R&D), product innovation, and end-user launches to hold a strong position in the mastitis industry. Key players in the global mastitis market include-
Collaboration and Partnership
| Report Attributes | Report Details |
| Study Timeline |
2019-2032 |
| Market Size in 2032 (USD Billion) | USD 3.16 Billion |
| CAGR (2025-2032) | 6.2% |
| By Disease Type |
|
| By Treatment |
|
| By Diagnostics |
|
| By End User |
|
| By Region |
|
| Key Players |
|
| North America | U.S. Canada Mexico |
| Europe | U.K. Germany France Spain Italy Russia Benelux Rest of Europe |
| APAC | China South Korea Japan India Australia ASEAN Rest of Asia-Pacific |
| Middle East and Africa | GCC Turkey South Africa Rest of MEA |
| LATAM | Brazil Argentina Chile Rest of LATAM |
| Report Coverage |
|
Themastitis market is estimated to reach over USD 3.16 Billion by 2032 from a value of USD 1.85 Billion in 2024 and is projected to grow by USD 1.96 Billion in 2025, growing at a CAGR of 6.2% from 2025 to 2032.
The mastitis report includes specific segmentation details for disease type, treatment, diagnostics, end user, and regions.
In the mastitis market, vaccines is the fastest-growing segment during the forecast period.
The mastitis marketis being shaped by several key trends including integration of AI and IoT-driven sensors for real-time milk analysis and global shift toward selective dry cow therapy and non-antibiotic alternatives like vaccines and bacteriophages. Further, this transformation is fueled by the transition toward precision livestock farming, where rapid molecular diagnostics and data-driven monitoring allow for early intervention at the sub-clinical stage to preserve both milk quality and farm profitability.
The key participants in the mastitis marketare Zoetis Inc. (U.S.), Merck Animal Health (U.S.), Boehringer Ingelheim (Germany), Elanco Animal Health (U.S.), Ceva Santé Animale (France), Dramiński S.A. (Poland), DeLaval (Sweden), GEA Group (Germany), Lely (Netherlands), Virbac (France), and others.